Tower Research Capital LLC (Trc) Chinook Therapeutics, Inc. Transaction History

Tower Research Capital LLC (Trc)

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$18.66 - $38.58 $29,669 - $61,342	-1,590 Reduced 31.62%	3,439 $132,000
Q1 2023 May 09, 2023	BUY	$21.53 - $26.8 $86,141 - $107,226	4,001 Added 389.2%	5,029 $116,000
Q4 2022 Feb 10, 2023	SELL	$18.63 - $27.35 $16,189 - $23,767	-869 Reduced 45.81%	1,028 $27,000
Q3 2022 Nov 10, 2022	SELL	$17.51 - $23.37 $334,248 - $446,109	-19,089 Reduced 90.96%	1,897 $37,000
Q2 2022 Aug 15, 2022	BUY	$12.59 - $18.8 $209,573 - $312,944	16,646 Added 383.55%	20,986 $367,000
Q1 2022 May 12, 2022	SELL	$12.02 - $16.69 $117,639 - $163,345	-9,787 Reduced 69.28%	4,340 $71,000
Q4 2021 Feb 14, 2022	BUY	$10.69 - $16.83 $100,806 - $158,706	9,430 Added 200.77%	14,127 $230,000
Q3 2021 Nov 15, 2021	BUY	$11.5 - $14.86 $4,818 - $6,226	419 Added 9.79%	4,697 $60,000
Q2 2021 Aug 16, 2021	BUY	$13.6 - $18.98 $36,910 - $51,511	2,714 Added 173.53%	4,278 $60,000
Q1 2021 May 17, 2021	SELL	$14.17 - $19.11 $37,833 - $51,023	-2,670 Reduced 63.06%	1,564 $24,000
Q4 2020 Feb 16, 2021	BUY	$11.9 - $20.91 $50,384 - $88,532	4,234 New	4,234 $67,000

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.